olaparib BRCA1 Loss, +3 more biomarkers Breast Carcinoma Early stage, +1 more state Adjuvant olaparib targeted therapy
olaparib ATM Loss, +27 more biomarkers Prostate Carcinoma Castration-resistant, +1 more state Subsequent line olaparib targeted therapy
rucaparib BRCA1 Loss, +3 more biomarkers Prostate Carcinoma Castration-resistant, +1 more state Subsequent line rucaparib targeted therapy
bevacizumab + olaparib BRCA1 Loss, +4 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Advanced Maintenance bevacizumab, +1 more drug targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Pancreatic Adenocarcinoma Metastatic Maintenance olaparib targeted therapy
niraparib BRCA1 Loss, +4 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Advanced Subsequent line niraparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Advanced Maintenance olaparib targeted therapy
talazoparib BRCA1 Loss, +3 more biomarkers Breast Carcinoma Locally advanced, +1 more state talazoparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Breast Carcinoma Metastatic Subsequent line olaparib targeted therapy
olaparib BRCA1 Loss, +3 more biomarkers Ovarian Carcinoma Advanced Subsequent line olaparib targeted therapy
rucaparib BRCA1 Loss, +3 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Subsequent line rucaparib targeted therapy
bevacizumab + olaparib BRCA1 Loss, +3 more biomarkers Fallopian Tube Carcinoma, +2 more conditions Stage II, +2 more states Maintenance bevacizumab, +1 more drug targeted therapy